Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW856553 safety, tolerability, pharmacodynamics and pharmacokinetics in COPD
2006-000729-70Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GW856553 with Placebo (2 arms). Primary endpoints: Safety and tolerability of GW856553 in patients with COPD, Systemic anti-inflammatory activity of GW856553 and 1 more. Started Apr 2006; status: completed.
02
Drugs
losmapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-000729-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000729-70.